Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments.
Melioidosis is a life-threatening bacterial infection caused by Burkholderia pseudomallei. Some antibiotics used to treat melioidosis can induce filamentation in B. pseudomallei. Despite studies on the mechanism of virulence of the bacteria, the properties of B. pseudomallei filaments and their impact on virulence have not been investigated before. To understand the characteristics of antibiotic-induced filaments, we performed in vitro assays to compare several aspects of virulence between normal, nonfilamentous and filamentous B. pseudomallei. Normal, nonfilamentous B. pseudomallei could cause the lysis of monocytic cells, while filaments induced by sublethal concentrations of ceftazidime, ofloxacin, or trimethoprim show decreased lysis of monocytic cells, especially after prolonged antibiotic exposure. The motility of the filamentous bacteria was reduced compared to that of nonfilamentous bacteria. However, the filamentation was reversible when the antibiotics were removed, and the revertant bacteria recovered their motility and ability to lyse monocytic cells. Meanwhile, antibiotic resistance developed in revertant bacteria exposed to ceftazidime at the MIC. Our study highlights the danger of letting antibiotic concentration drop to the MIC or sub-MICs during antibiotic treatment of melioidosis. This could potentially give rise to a temporary reduction of bacterial virulence, only to result in bacteria that are equally virulent but more resistant to antibiotics, should the antibiotics be reduced or removed.
Chen
Kang
K
Department of Biochemistry, National University of Singapore, 8 Medical Dr., Singapore 117597, Singapore.
Sun
Guang Wen
GW
Chua
Kim Lee
KL
Gan
Yunn-Hwen
YH
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000472:pathogenicity / Q000648:ultrastructure; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D014774:Virulence
D000900:Anti-Bacterial Agents; D016207:Cytokines
Curr Opin Infect Dis. 2004 Apr;17(2):131-6
15021053
Antimicrob Agents Chemother. 1999 May;43(5):1013-9
10223908
Antimicrob Agents Chemother. 1977 Dec;12(6):736-44
337891
Rev Infect Dis. 1979 May-Jun;1(3):434-67
45147
J Antimicrob Chemother. 1981 Jan;7(1):57-63
7009535
J Antimicrob Chemother. 2000 Jan;45(1):15-25
10629008
J Infect Dis. 2000 Mar;181(3):1014-9
10720525
Med Microbiol Immunol. 1999 Nov;188(2):91-7
10753061
Br J Clin Pharmacol. 2000 Aug;50(2):184-91
10930972
Cell Microbiol. 2000 Aug;2(4):265-73
11207583
Microbiol Immunol. 2001;45(4):307-13
11386421
Infect Immun. 2002 Feb;70(2):504-11
11796576
Curr Opin Infect Dis. 2002 Apr;15(2):127-32
11964912
J Chemother. 1991 Jan;3 Suppl 1:105-11
12041741
Infect Immun. 2003 Apr;71(4):1622-9
12654773
Chest. 2004 Feb;125(2 Suppl):62S-69S; quiz 69S
14872002
Antimicrob Agents Chemother. 1981 May;19(5):901-10
6271051
J Med Microbiol. 1987 Feb;23(1):83-8
3546699
Rev Infect Dis. 1989 May-Jun;11(3):413-25
2665001
J Infect Dis. 1992 Mar;165(3):561-4
1538161
J Infect Dis. 1992 Jun;165(6):1033-41
1583320
Scand J Infect Dis. 1991;23(6):745-54
1815338
Nature. 1992 Jul 9;358(6382):167-9
1614548
Infect Immun. 1994 Nov;62(11):4975-80
7927777
Eur J Clin Microbiol Infect Dis. 1994;13 Suppl 1:S43-51
7821304
J Med Microbiol. 1995 May;42(5):362-6
7752216
J Infect Dis. 1995 Dec;172(6):1519-27
7594711
Antimicrob Agents Chemother. 1995 Oct;39(10):2356-8
8619598
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4197-201
8633040
J Antimicrob Chemother. 1996 Jan;37(1):188-90
8647763
J Antimicrob Chemother. 1995 Dec;36(6):885-7
8821587
Infect Immun. 1996 Dec;64(12):4952-9
8945532
J Exp Med. 1998 Apr 6;187(7):1069-79
9529323
Annu Rev Microbiol. 1998;52:591-625
9891809
J Ultrastruct Res. 1969 Jan;26(1):31-43
4887011